INTRODUCTION
Visceral leishmaniasis (VL, kala-azar) is the most serious infection caused by the protozoan parasite Leishmania spp. Transmitted by the bites of sand flies, promastigotes are transformed rapidly into amastigotes that invade macrophages mainly in liver, spleen, and bone marrow. The infection may be asymptomatic and symptoms, including fever, weight loss, and hepatosplenomegaly, may appear months after the initial infection. Symptomatic VL is usually fatal if untreated.
In India during 2000-2002, there were 18,472 recorded cases of VL, mostly in the Bihar region. 1 However, disease incidence is probably underestimated by at least eight-fold. 2, 3 In Bihar, clinical resistance to pentavalent antimony generates treatment failure rates in excess of 50%. [4] [5] [6] Consequently, amphotericin B (AmB) is the standard of care in expert centers in India. Although highly effective, AmB requires intravenous administration over 30 days, has significant toxic effects, and treatment costs are relatively high. 4, [7] [8] [9] Liposomal AmB has improved tolerability, but is too expensive for most patients in Bihar. 10 Intramuscular paromomycin was approved for treatment of patients with VL in India in 2006. It has the same efficacy as AmB, 7 a 21-day treatment duration, and a low purchase cost, although parenteral therapy may limit its usefulness in a public health setting. Miltefosine was the first oral therapy available for VL and a significant breakthrough. [11] [12] [13] However, a four-week treatment schedule and a long-half life may make it vulnerable to resistance development if given as monotherapy, and teratogenicity is an issue for its use in women. 14 The recent emphasis on Leishmania elimination in India, Nepal and Bangladesh, 3, 15 sustains a need for alternative, affordable, well-tolerated, and effective oral therapies.
Sitamaquine (WR6026) is an 8-aminoquinoline under investigation as an oral VL therapy. Two initial phase II clinical studies of 1.5−3.0 mg/kg/day of sitamaquine for 28 days in India and Africa showed maximal efficacy with 1.75 or 2 mg/kg/day. 16, 17 Clinical symptoms resolved rapidly in both studies. 16, 17 In the study in India, day 14 splenic aspirates were parasite negative in 96 (82%) of 117 patients overall and in 26 (93%) of 28 patients in the cohort receiving 2.0 mg/kg/day. 16 These data suggested that a shorter therapy course may be possible. 16, 17 Some renal adverse events were reported; most occurred after day 21, generally in the groups receiving higher doses (> 2.0 mg/kg/day). 16, 17 A shorter treatment course could potentially enhance compliance with out-patient oral therapy, improve tolerability, and reduce costs if adequate efficacy could be maintained, particularly given a possible use in combination therapy.
The purpose of our phase IIb, open-label, randomized, clinical trial in VL patients was to determine the multiple-dose pharmacokinetic profile of sitamaquine and its metabolite desethyl-sitamaquine after administration of 2 mg/kg/day of sitamaquine with or without food for 21 days. This study also carefully investigated sitamaquine safety results from previous sitamaquine studies [16] [17] [18] [19] [20] and compared the safety and efficacy of a 21-day course of oral sitamaquine with a 30-day course of AmB for the treatment of VL.
PATIENTS AND METHODS
This prospective, open-label, randomized clinical study was conducted during August 2006-September 2007 at three centers in Bihar, India. Study procedures followed Good Clinical Practice and the Declaration of Helsinki. The protocol was reviewed and approved by the independent ethics committee for each study site, the Drug Controller General of India, and the Indian Council of Medical Research. All study participants or their guardians provided written informed consent; assent was required from children able to understand the study.
Study participants. Abstract. This randomized, open-label study of patients in India with visceral leishmaniasis (VL) investigated the effect of food on sitamaquine and desethyl-sitamaquine pharmacokinetics. Patients were randomized to receive oral sitamaquine, 2 mg/kg/day, once a day for 21 days across four cohorts (n = 41) (fasted/fed, fed/fasted, fed/fed, and fasted/fasted) over two periods (days 1−10 and 11−21), or intravenous amphotericin B (AmB), 1 mg/kg every other day for 30 days (n = 20). Mean day 21 pharmacokinetics across the four cohorts were sitamaquine, area under curve (AUC) (0−τ) = 6,627−8,903 ng.hr/mL, AUC (0−16) = 4,859−6,633 ng.hr/mL, maximum plasma concentration ( C max ) = 401−570 ng/mL, apparent terminal half-life ( t 1/2 ) = 18.3−22.8 hr, time to reach C max ( t max ) = 3.5−6 hr; and desethyl-sitamaquine, AUC (0−τ) = 2,307−3,163 ng.hr/ mL, C max = 109−154 ng/mL, t 1/2 = 23.0−27.9 hr, t max = 2−10 hr, with no significant food effect. On-therapy adverse events were observed for sitamaquine in 4 (10%) of 41 patients and for AmB in 17 (85%) of 20 patients. The final clinical cure (day 180) was 85% (95% confidence interval = 70.8-94.4%) for sitamaquine and 95% (95% confidence interval = 75.1-99.9) for AmB. Sitamaquine can be taken regardless of food intake, was generally well tolerated, and showed potential efficacy in patients with visceral leishmaniasis. splenic aspirates or bone marrow. Exclusion criteria were renal, hepatic or biliary disease; renal or hepatic impairment; cardiac disease, arrhythmia, or conduction abnormalities; clinically relevant electrocardiogram (ECG) results or laboratory values; serious underlying disease or infection; glucose-6-phosphate dehydrogenase deficiency (based on phenotype testing); positive results for antibodies against human immunodeficiency virus, hepatitis B surface antigen, or antibodies to hepatitis C virus; contraindication to splenic or bone marrow aspiration; hypersensitivity to study treatments; treatment with an established anti-leishmania drug within 30 days or 5 half-lives (whichever was longer) of the start of the study; or treatment with prohibited medication. Pregnant or nursing women were excluded; a negative urine pregnancy test result was required from female patients at screening and before dosing, plus an agreement to use contraception for two weeks after the last treatment dose.
Study design and interventions. No formal sample size calculation was performed. Target enrollment was 60 patients to achieve 32 evaluable patients in the sitamaquine group (8 per cohort) and 16 in the AmB cohort, assuming 20% discontinuation. Patients were randomized into blocks of 12 in the ratio 1:1:1:1:2 to one of four sitamaquine cohorts or AmB ( Figure 1 ). Treatment was allocated by using the GlaxoSmithKline Registration and Medication Ordering System (RAMOS).
Randomized patients received either oral sitamaquine, 2 mg/kg/day, once a day, for 21 days (GlaxoSmithKline, Harlow, United Kingdom), or intravenous AmB given initially as 1 mg over 30 minutes and titrated over the first few treatment days to 1 mg/kg, every other day, for 30 days. Until ( Figure 1 ). Vomiting within one hour of dosing resulted in re-dosing. Vomiting within one hour of re-dosing led to withdrawal from the study and administration of rescue medication (liposomal amphotericin B). Therapy interruptions were allowed for AmB but not for sitamaquine. All patients were hospitalized during treatment, plus three days for those treated with sitamaquine or 2 days for those treated with AmB. Follow-up continued for 180 days post-study start with scheduled visits at days 49, 90, and 180 for those treated with sitamaquine and days 58, 90, and 180 for those treated with AmB.
Analytical methods. Venous blood samples (3 mL) for pharmacokinetic analysis were collected on days 1, 10, and 21 immediately before dosing and at 1, 2, 3, 4, 6, 10, 16, and 24 hours post-dose. Additional samples were obtained on days 23 and 24 to approximate 48 hours and 72 hours after the last sitamaquine dose. After solid-phase extraction from human plasma, sitamaquine and desethyl-sitamaquine concentrations were determined at a central laboratory (Aptuit Inc., Edinburgh, Scotland) by using high-performance liquid chromatography with tandem mass spectrometric detection, a TurbolonSpray ® interface (Applied Biosystems, Foster City, CA) and multiple reaction monitoring. The method was validated over the range 1−1000 ng/mL for both analytes using 50 μL of human plasma. Spiked standards and quality control (QC) samples were extracted daily. Within-run precision and bias, calculated by using interpolated concentrations of QC samples (prepared at 2.5, 500, 800, and 5,000 ng/mL of sitamaquine and desethyl-sitamaquine), were less than 10% across all QC levels, demonstrating acceptable performance.
Pharmacokinetic assessment. Pharmacokinetic analysis of sitamaquine and desethyl-sitamaquine concentration-time data was conducted by using a non-compartmental Model 200 in WinNonlin Professional Edition (Version 5.2; Pharsight Corp. Mountain View, CA). Actual elapsed time after dosing from the individual concentration-time profiles for evaluable patients was used to derive the following pharmacokinetic parameters: area under the concentration−time curve over the dosing interval (AUC (0−τ) ); maximum observed plasma concentration ( C max ); time to reach C max ( t max ); terminal phase elimination rate constant (λz); apparent terminal half-life ( t 1/2 ); and observed accumulation ratio (Ro). For AUC (0−τ) , where τ = 24 hours, i.e. AUC (0−24) , physiologically unfeasible or missed concentrations at the 24-hour time point for 17 patients required substitution with AUC (0−16) . To express pharmacokinetic parameter variability, pooled betweensubject coefficient of variation and within-subject co-efficient of variation were calculated by using the relevant residual variance.
Safety assessment. Physical examinations were performed and vital signs and adverse events were assessed at screening, baseline, throughout treatment, and at follow-up visits. Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events v3.0, 21 or if not listed, the Division of Microbiology and Infectious Diseases Adult Toxicity Table. 22 Grade 3 or higher toxicities were deemed clinically relevant. Dose-limiting toxicity required study therapy to be stopped and rescue medication initiated. Serious adverse events were defined as those resulting in death (or life-threatening), hospitalization or prolonged hospitalization, disability or incapacity, or a congenital anomaly or birth defect, or were otherwise medically significant.
Venous blood samples (3 mL) for clinical laboratory analyses and urine samples for urinalysis were obtained at screening, baseline and days 5, 10, 16, 21, 90, and 180 for both study treatments and at day 49 for sitamaquine and days 30 and 58 for AmB. Clinical laboratory tests and urinalysis were performed at a central laboratory in Mumbai, India.
Duplicate, full 12-lead ECGs (ELI 150; Mortara Instruments, Milwaukee, WI) were recorded at screening, baseline (within 24 hours before dosing on day 1), and days 4, 9, 15, plus days 22 and 31 for sitamaquine-treated patients and days 49 and 58 for AmB-treated patients. On-treatment ECGs were recorded four hours after dosing. Transthoracic two-dimensional echocardiograms were performed at screening, on days 22 and 49 for sitamaquine-treated patients, and days 31 and 58 for AmB-treated patients. Ejection fraction was estimated by using the modified Simpson's rule. ECGs and two-dimensional echocardiograms were reviewed locally within 24 hours, but the safety analysis used readings by an independent cardiologist blinded to treatment and recording time.
Efficacy assessment. Spleen size was measured by using ultrasound on day 1 and at end of therapy. Splenic aspirate (or bone marrow aspirate if splenic aspirate could not be obtained) was conducted at screening, end of therapy, day 90, and day 180 if clinical symptoms indicated relapse and on study withdrawal if the patient had received study therapy for at least 14 days. Samples were stained with Giemsa and parasite load was quantified by using the Leishmania index by a microscopist blinded to study treatment. 23 At end of therapy, if the Leishmania index was +1, splenic aspirate was repeated 28 days later; if the Leishmania index was ≥ +2, the patient was classified as a treatment failure, withdrawn from the study, and given rescue medication. Efficacy endpoints were initial parasitologic cure (parasite-negative splenic aspirate at end of therapy or, if the Leishmania index was +1, a parasite-negative splenic aspirate 28 days later), and final clinical cure (initial parasitologic cure and no evidence of relapse at day 180).
Statistical analysis. Primary pharmacokinetic endpoints were plasma AUC (0−τ) , AUC (0-16) , C max , t max , and Ro; t 1/2 was a secondary endpoint. All statistical analysis was performed by using SAS Version 8.2 (SAS Institute Inc., Cary, NC).
Food effect. The effect of food on sitamaquine plasma AUC (0-τ) , AUC (0) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , and C max and on desethyl-sitamaquine AUC (0-τ) and C max , was evaluated at day 10 and day 21. After log e transformation, a linear mixed-effects model was used, fitting day and treatment (fasted or fed) as fixed effects and patient as a random effect. Point estimates and associated 90% confidence intervals (CIs) for the difference in each pharmacokinetic parameter between fed and fasted treatment regimens were calculated. These values were exponentially back transformed to provide point estimates and 90% CIs for the fed:fasted ratio. The standard 90% CI bioequivalence range of 0.80−1.25 was used to interpret results. Additional effects such as weight and treatment dose were explored as covariates. For t max , untransformed data were analyzed nonparametrically by using the Wilcoxon matched pairs method, 24 and point estimates and 90% CIs were constructed for the estimated median difference fed-fasted.
Accumulation ratio. Sitamaquine Ro was calculated by statistical analysis of sitamaquine and desethyl-sitamaquine AUC (0-τ) . After log e transformation, a linear mixed-effects model was fitted and included the day, food status (fasted or fed), and their interaction as fixed effects and patient as a random effect. Within each food status, Ro was estimated by comparing values at day 10 or day 21 with values at day 1. Point estimates and associated 90% CIs for day 10 or day 21 versus day 1 for each food state were exponentially back transformed into their original scale. In addition, a combined estimate for Ro over fasted and fed treatments was determined. Additional effects such as weight and treatment dose were explored as covariates.
Secondary outcomes. All other pharmacokinetic, safety, and efficacy comparisons were investigated by using descriptive statistics. For safety and efficacy evaluations, combined sitamaquine cohorts were compared with AmB.
RESULTS

Patients.
The study design is shown in Figure 1 . Of 176 patients screened, 61 were randomized; 41 received sitamaquine and 20 received AmB. There were four early withdrawals in the sitamaquine group (two adverse events, one lack of efficacy, and one relapse) and one in the AmB group (adverse event). Baseline characteristics are shown in Table 1 ; these were similar across cohorts, except for sex. All patients were Asian. The Leishmania index was 1 or 2 in 80% of patients. Mean (SD) compliance with study medication was 97.8% (11.5%) for sitamaquine and 96.3% (14.9%) for AmB.
Pharmacokinetic outcomes. Sitamaquine and desethylsitamaquine day 21 mean plasma concentration−time curves are shown in Figure 2 . Sitamaquine and desethyl-sitamaquine pharmacokinetic parameters by cohort and day are shown in Table 2 . Sitamaquine was slowly metabolized to desethylsitamaquine, and AUC (0−τ) and C max values were higher after multiple dosing at day 10 compared with day 1. For sitamaquine and desethyl-sitamaquine, AUC (0−τ) was greatest at day 10 in all cohorts.
Food effect. Within-subject crossover comparison of cohorts 1 and 2 are shown in Table 3 . Point estimates close to unity indicated no food effect on sitamaquine AUC (0−τ) , AUC (0−16) , or C max , or on desethyl-sitamaquine AUC (0−τ) or C max . Intrasubject variability for AUC (0−τ) and C max was moderate to high for sitamaquine and desethyl-sitamaquine (maximum 29.6% and 24.0%, respectively). Adding body weight and dose to the model as covariate effects showed similar results. In cohorts 1 and 2, a within-subject crossover comparison indicated that t max was 1.52 hours longer (90% CI = 0-3.92) for sitamaquine and 3.00 hours longer (90% CI = −1.00 to 7.50) for desethylsitamaquine in a fed versus fasted state; these differences were not significant, as indicated by the 90% CIs including 0. Between-subject parallel-group comparison of cohorts 3 and 4 showed sitamaquine t max was 0.17 hours shorter for the fed versus fasted state on day 10 (90% CI = −2.25 to 2.00) and no difference for day 21 (90% CI = −1.03 to 4.00). For was not calculated at days 1 and 10 because of the lack of adequate elimination phase concentration−time data. ** n = 4.
desethyl-sitamaquine, t max was 1.25 hours shorter for the fed versus fasted state on day 10 (90% CI = −4.92 to 1.00) and 6 hours longer in a fed versus fasted state at day 21 (90% CI = 0-8.00). However, for all between-subject comparisons of t max , confidence intervals were wide and included 0, indicating that none of the differences were significant. Accumulation ratio. Results of assessment of Ro for sitamaquine and desethyl-sitamaquine are shown in Table 4 . For combined sitamaquine cohorts, AUC (0−τ) values for fasted and fed patients increased 1.4-fold on day 10 and decreased marginally on day 21 compared with day 1. The extent of accumulation was greater for desethyl-sitamaquine; combined AUC (0−τ) increased from day 1 to day 10 by 6.8-fold and to day 21 by 5.2-fold. Adding body weight and dose as covariates to the model showed similar results.
Safety outcomes. Adverse events. During therapy, 4 (10%) of 41 patients in the sitamaquine group experienced an adverse event versus 17 (85%) of 20 patients in the AmB group ( Table 5 ) . No serious adverse events occurred during treatment and two occurred during follow-up. Both patients received sitamaquine, neither event was considered drug-related by the investigator: acute gastroenteritis four months after completing therapy, resulting in death and study withdrawal; and cholelithiasis. Adverse events led to study withdrawal for two other patients: one received sitamaquine (grade 4 toxicity: low neutrophil count at day 7, grade 3 toxicity at baseline), and one received AmB (low creatinine clearance at day 16); neither was considered drug related. Two patients stopped treatment prematurely but completed follow-up: one received sitamaquine (increased protein:creatinine ratio at day 16) and one AmB (request of the patient at day 15).
Hematologic results. Baseline, end of therapy, and change from baseline values for key hematologic parameters are shown in Table 6 . For both treatment groups, mean hemoglobin level decreased initially, followed by a gradual recovery after day 5. In sitamaquine-treated patients, methemoglobin levels increased after day 5 ( Figure 3A ) , peaking between days 16 and 21, but returning to baseline by day 49 in all patients. Four patients had methemoglobin levels of 5−9.9% and one patient had a value > 10% (maximum = 10.8%). No clinical signs or symptoms were associated with increased methemoglobin levels and no treatment was necessary.
Clinical chemistry results. Baseline, end of therapy, and change from baseline values for key clinical chemistry parameters are shown in Table 6 . Mean values for alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase (AST) levels were increased at baseline, although toxicities were grade 2 or less. For both study treatments, hepatic enzyme levels generally decreased during treatment and remained stable after the end of therapy. One AST grade 3 toxicity occurred at day 58 in the AmB group. Mean total bilirubin level was similar between treatment groups with no post-baseline grade 3 or 4 toxicities. Mean serum creatinine level remained stable in the sitamaquine group throughout the study, but increased in the AmB group, peaking at 100 μmol/L on day 21 ( Figure 3B ). There were no grade 3 or 4 toxicities for serum creatinine in either group. Ten (50%) patients in the AmB group had grade 1 or 2 toxicities during therapy, which were reversible in all cases. At day 90, one patient in each treatment group had a grade 1 toxicity, which was considered unrelated to study treatment. Mean creatinine clearance decreased in patients treated with AmB until day 5, then recovered slowly, with another decrease at approximately day 21 ( Figure 3C and Table 7 ). In the sitamaquine group, creatinine clearance remained generally stable.
Urinalysis. The urine protein:creatinine ratio was > 1.0 in 7 (17%) of 41 patients during sitamaquine treatment; all had normal baseline values ( Table 6 and Figure 3D ). Six patients had increases of > 3.5 during treatment (mostly after day 16) and maximum changes occurred at approximately day 21. Proteinuria was asymptomatic and reversible and returned to normal/baseline values within 20 days or by the next scheduled visit, except for one patient where the protein:creatinine ratio improved but remained increased at day 180. Plasma sitamaquine and desethyl-sitamaquine AUC (0−τ) and C max for the seven patients with protein:creatinine ratios > 1.0 during treatment were within the range of those for patients with normal protein:creatinine ratios. There were no clinically relevant changes in protein:creatinine ratio for AmBtreated patients. Hematuria (> 3 erythrocytes/high-power [HP] field) was observed during treatment in 10 (24%) of 41 patients treated with sitamaquine (maximum value = 10-12 erythrocytes/HP field) and 3 (15%) of 20 patients treated with AmB (maximum value = 20-25 erythroctes/HP field) ( Figure 4 ). Hematuria resolved after therapy completion in both treatment groups. Two patients (both women) in the sitamaquine-treated group had unexplained hematuria (> 100 erythrocytes/HP field) at day 180 and no other findings on renal function or urinalysis. Increased urine leukocyte count was observed for two patients in the AmB-treated group and none in the sitamaquine-treated group.
Cardiac safety. One patient in each treatment group had abnormal ECGs at baseline (flat T waves) and end of therapy. Abnormal end of therapy ECGs were recorded for three other patients receiving sitamaquine (flat T waves, sinus tachycardia, first-degree atrioventricular block), and two receiving AmB (ST depression, left anterior hemiblock). There were no differences in QTc changes from baseline between treatment groups. Maximum changes from baseline (≥ 60 msec) were observed in one (3%, QTcB) or two (5%, QTcF) sitamaquinetreated patients, and one (5%, QTcB or QTcF) AmB-treated patient on day 15. In the AmB group, further changes ≥ 60 msec from baseline were observed: two (11%) on day 4 and one (6%) on day 58 (QTcB, QTcF). Maximum values for individual * CI = confidence interval; CVw% = within-subject coefficient of variation. † Point estimate is the ratio of adjusted geometric means between repeat dosing days (days 21 or 10) and single dose day 1. patients were 478 msec on day 22 for sitamaquine and 483 msec on day 58 for AmB. None of the patients with ECG changes had any cardiologic adverse events noted. For twodimensional echocardiogram, there was no clinically relevant difference between treatment groups in mean left ventricular ejection fraction at end of therapy or follow-up (day 49 for sitamaquine and day 58 for AmB). There were no clinically relevant changes from baseline in creatine kinase musclebrain in either treatment group ( Table 6 ). Troponin I values were unremarkable during treatment ( Table 6 ), except for one ( Table 1 ) was similar for the two treatment groups: −2.58 cm (1.4 cm) for sitamaquine (day 22) and −2.38 cm (1.8 cm) for AmB (day 31). When we adjusted for treatment, baseline spleen size and center produced similar results: −2.52 cm for sitamaquine, −2.70 cm for AmB (95% CI for difference = −0.549 to 0.924). The mean (SD) change in body weight from baseline ( Table 1 ) to the end of therapy was 0.53 kg (0.8 kg) for sitamaquine and 1.5 kg (1.2 kg) for AmB. Approximately half of all patients were febrile at baseline ( Table 1 ) . One-fourth of the febrile patients had a temperature < 38°C by day 1 (95% CI = 0.1-7.2) in the sitamaquine-treated group versus day 8 (95% CI = 1.0-2.0) in the AmB-treated group. All patients were afebrile by day 36 in the sitamaquine group and day 15 in the AmB group.
DISCUSSION
This phase IIb, randomized, open-label, prospective study found no effect of food on sitamaquine or desethyl-sitamaquine pharmacokinetics in VL patients. These data suggest that sitamaquine can be dosed regardless of food intake.
Drug accumulation was expected to be between 1-fold and 2-fold for sitamaquine and its desethyl metabolite on the basis of the estimated t 1/2 of 18−28 hours, i.e. expected Ro was 1.44 ( t 1/2 /dosing interval). Sitamaquine Ro, assessed relative to day 1 was 1.37 at day 10 and 0.94 at day 21, which were somewhat lower than expected. Ro for desethyl-sitamaquine, relative to day 1 was 7.0 at day 10 and 5.75 at day 21, which were considerably higher than expected. These results could be explained by sitamaquine induction of its own metabolism after repeat dosing. Another possible explanation may be the improving health of the patients during the 21-day dosing period. In particular, sitamaquine is metabolized by several cytochrome P450 pathways and improved liver function, as shown by decreases in hepatic enzymes, may have resulted in increased sitamaquine metabolism. However, further investigations are required to better understand these findings.
Treatment with sitamaquine was generally well tolerated; 10% of patients reported adverse events versus 85% with AmB. This difference was mostly because of infusion reactions with AmB. These adverse events are broadly consistent with the known safety profile for AmB. 7, 25, 26 This study also carefully investigated hematologic, hepatic, renal, and cardiac safety signals identified in pre-clinical and previous clinical sitamaquine studies. [16] [17] [18] [19] [20] Increased methemoglobin levels are a known class effect of 8-aminoquinolines; all patients are at risk regardless of glucose-6-phosphate dehydrogenase status. In the previous phase II study in India (sitamaquine, 1.5−2.5 mg/kg for 28 days), laboratory reports showed 40 (33%) of 120 patients with methemoglobin level increases ≥ 10% (maximum = 22.5%, dose = 1.75 mg/kg/day); six patients were symptomatic. 16 In the current study, methemoglobin levels were 5−9.9% for four patients and ≥ 10% in one patient (maximum = 10.8%). Methemoglobin level increases were reversible after the end of therapy and asymptomatic. Sitamaquine caused methemoglobin level increases from day 5. Therefore, it is unlikely that the shorter sitamaquine treatment duration in the current study explains the lower effect on methemoglobin levels than in the previous phase II study in India and these findings remain unexplained.
No hepatic adverse events were reported for either treatment in this study, and there was no evidence of hepatotoxicity. Hepatic function was generally abnormal at baseline and tended to normalize during therapy in both treatment groups. Results of previous studies are generally consistent with these findings. In the phase II sitamaquine study in Kenya, 8 (8%) of 97 patients had increased AST levels as an adverse event, although six of eight patients had increased AST levels at baseline. 17 There were no reports of hepatic enzyme adverse events in the previous phase II study in India. 16 Nephrotoxicity is a known safety issue with AmB, 8 and serum creatinine levels were increased and creatinine clearance decreased versus baseline. Renal function was generally stable with sitamaquine. Two sitamaquine-treated patients had a transient decrease in creatinine clearance versus baseline (25% and 46%); values returned to baseline within two weeks after completion of therapy. Two patients had asymptomatic hematuria (normalized by day 90 and day 180). Proteinuria was the most significant renal safety finding with sitamaquine and was observed in 7 of 41 patients, 6 with a protein:creatinine ratio increased from baseline by > 3.5. Proteinuria was observed after day 16 and maximum changes were observed at approximately day 21. These changes were reversible after drug discontinuation. One patient with an increased urine protein:creatinine ratio withdrew from the study on day 16. All patients with proteinuria were asymptomatic and none showed development of nephrotic syndrome or glomerulonephritis. There were no serious renal adverse events. This finding is in contrast to previous clinical studies with sitamaquine in which glomerulonephritis, nephrotic syndrome, and acute renal failure were reported. [16] [17] [18] [19] [20] However, most of these events occurred at sitamaquine doses > 2-3.5 mg/kg/day after day 21 of a 28-day therapy course. [16] [17] [18] [19] [20] Our findings suggest that sitamaquine, 2 mg/kg/day for 21 days, has reduced the incidence and severity of renal adverse events.
Cardiovascular effects had been seen in pre-clinical sitamaquine studies in dogs, although these were not corroborated in subsequent telemetered dog safety studies. Cardiomyocyte degeneration had also been noted in a monkey dose-ranging study. Previous clinical studies reported bradycardia and some non-specific ECG changes, but data were limited. 16, 17 In this study, non-specific ECG abnormalities were noted for patients in both treatment groups; there were no clinical symptoms or correlation with cardiac enzymes. There were no instances of bradycardia. Results for two-dimensional echocardiogram and cardiac enzymes provided no evidence of cardiotoxicity for either treatment group.
For sitamaquine, the final cure rate was 85% after 21 days of therapy, and these results are consistent with final cure rates from previous trials of sitamaquine, 2 mg/kg/day for 28 days, for patients from India (n = 28) and Africa (n = 61): 100% (95% CI = 85.2-100%) and 80.3% (95% CI = 68.2-89.4%), respectively. 16, 17 The small number of patients in our study and previous sitamaquine studies means that 95% CIs are broad (68.2-100%). Sitamaquine efficacy in VL remains to be proven in larger studies, possibly in combination with other drugs. Clinical efficacy with AmB was consistent with recent reports of VL patients in India. 25, 26 This study showed that sitamaquine can be administered regardless of food intake. Sitamaquine, 2.0 mg/kg/day for 21 days, was generally well tolerated, and although renal adverse events were evident, these events appeared to be reversible and manageable. The 21-day regimen had final cure rates similar to those of previous studies with 28-day therapy. These data indicate the potential usefulness of sitamaquine for treatment of patients with VL. The pharmacokinetic and safety findings are of particular use should the drug be used in a combination therapy.
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